Table 1 Patient characteristics
Patient ID | Gender | Age (years) | Site of evaluable disease | M1 classification | Previous treatments |
|---|---|---|---|---|---|
28 | M | 66 | Lymph nodes, lung, liver, pelvis | a | BIOCT |
29 | F | 43 | Lymph nodes, lung, liver, skin | c | BIOCT |
30 | M | 69 | Lymph nodes, skin, bone | c | BIOCT |
31 | M | 57 | Lymph nodes, skin | a | BIOCT |
32 | M | 59 | Lymph nodes, lung, liver | c | BIOCT |
33 | F | 44 | Liver, skin | c | BIOCT, anti-CTLA4Ab (interrupted after 2 cylces due to grade IV toxicity) |
34 | F | 45 | Lung, lymph nodes, soft tissue | b | CT and RT |
35. | M | 73 | Lymph nodes, soft tissue, peritoneum | a | Surgery and RT |
36 | M | 68 | Skin, lung | b | BIOCT |
37 | F | 35 | Pelvis, lymph nodes,skin, peritoneum, lung | b | CT, anti-CTLA4Ab |
38 | M | 51 | Lymph nodes, skin, lung | c | anti-CTLA4Ab, CT |
39 | M | 62 | Lymph nodes, skin, adrenal gland | c | Leg Stopflow CT, ECT |
40 | M | 47 | Lymph nodes,skin, peritoneum | c | anti-CTLA4Ab, CT, RT |
41 | F | 57 | Lymph nodes | a | IFN, antiCD137Ab, CT |
42 | M | 49 | Lymph nodes, soft tissue, colon | c | CT |
43 | M | 60 | Adrenal gland, soft tissue, lung | c | CT |
44 | M | 57 | Lung, liver, lymph nodes, soft tissue | c | CT, IFN |
Summary | Male 12 | Median | M1a:4 | ||
M1b:3 | |||||
Female 5 | 57 (range 35–73) | M1c:10 |